Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
 1 a 10 de 10 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Anónimo. Abordaje de la hepatitis C. ¿Tiempos para la esperanza?. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-10. [Ref.ID 99823]
2.
Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Hézode C, Pockros PJ, Tran A, Yozviak J, Neau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015;313:1736-44. [Ref.ID 99085]
3. Cita con resumen
Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki J-P, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson S, Yin PD, for the UNITY-1 Study Group. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015;313:1728-35. [Ref.ID 99084]
4.Tiene citas relacionadas
Gane E. Hepatitis C beware—the end is nigh. Lancet 2014;384:1557-60. [Ref.ID 98307]
5.Tiene citas relacionadas Cita con resumen
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C-Y, Chang T-T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C-J, Sievert W, Bronowicki J-P, Thabut D, Lee Y-J, Kao J-H, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, on behalf of the HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384:1597-605. [Ref.ID 98304]
6. Cita con resumen
Liang TJ, Ghany MG. Therapy of hepatitis C. Back to the future. N Engl J Med 2014;370:2043-7. [Ref.ID 97487]
7. Cita con resumen
Editorial. Only just the begining of the end hof hepatiis C. Lancet 2014;383:281. [Ref.ID 97073]
8. Cita con resumen
Sherman RE, Li J, Shapley S, Robb M, Woodcock J. Expediting drug development - The FDA's new "breakthrough therapy" designation. N Engl J Med 2013;369:1877-80. [Ref.ID 96536]
9.Enlace a cita original
Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME. Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2013;75:931-43. [Ref.ID 95214]
10. Cita con resumen
Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24. [Ref.ID 92234]
Seleccionar todas
 
 1 a 10 de 10